Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis
| dc.contributor.author | Meltzer, Eli | |
| dc.contributor.author | Ratner, Paul | |
| dc.contributor.author | Bachert, Claus | |
| dc.contributor.author | Carr, Warner | |
| dc.contributor.author | Berger, William | |
| dc.contributor.author | Canonica, G. Walter | |
| dc.contributor.author | Hadley, James | |
| dc.contributor.author | Lieberman, Phil | |
| dc.contributor.author | Hampel, Frank C. | |
| dc.contributor.author | Mullol, Joaquim | |
| dc.contributor.author | Munzel, Ullrich | |
| dc.contributor.author | Price, David | |
| dc.contributor.author | Scadding, Glenis | |
| dc.contributor.author | Virchow, J. Christian | |
| dc.contributor.author | Wahn, Ulrich | |
| dc.contributor.author | Murray, Ruth | |
| dc.contributor.author | Bousquet, Jean | |
| dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en | 
| dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en | 
| dc.date.accessioned | 2020-06-16T10:45:01Z | |
| dc.date.available | 2020-06-16T10:45:01Z | |
| dc.date.issued | 2013-07 | |
| dc.description | Acknowledgements This study was funded by MedaPharma. | en | 
| dc.description.status | Peer reviewed | en | 
| dc.format.extent | 9 | |
| dc.format.extent | 245859 | |
| dc.identifier | 171119739 | |
| dc.identifier | b032e894-32e6-4db5-918f-9e59dd7eb949 | |
| dc.identifier | 84877679580 | |
| dc.identifier.citation | Meltzer, E, Ratner, P, Bachert, C, Carr, W, Berger, W, Canonica, G W, Hadley, J, Lieberman, P, Hampel, F C, Mullol, J, Munzel, U, Price, D, Scadding, G, Virchow, J C, Wahn, U, Murray, R & Bousquet, J 2013, 'Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis', International Archives of Allergy and Immunology, vol. 161, no. 4, pp. 369-377. https://doi.org/10.1159/000351404 | en | 
| dc.identifier.doi | 10.1159/000351404 | |
| dc.identifier.iss | 4 | en | 
| dc.identifier.issn | 1018-2438 | |
| dc.identifier.uri | https://hdl.handle.net/2164/14506 | |
| dc.identifier.vol | 161 | en | 
| dc.language.iso | eng | |
| dc.relation.ispartof | International Archives of Allergy and Immunology | en | 
| dc.subject | Allergic rhinitis | en | 
| dc.subject | Azelastine | en | 
| dc.subject | Fluticasone | en | 
| dc.subject | MP29-02 | en | 
| dc.subject | Responder analysis | en | 
| dc.subject | Severe chronic upper airway disease | en | 
| dc.subject | R Medicine (General) | en | 
| dc.subject.lcc | R1 | en | 
| dc.title | Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis | en | 
| dc.type | Journal article | en | 
Files
Original bundle
1 - 1 of 1
- Name:
- Meltzer_et_al_IAAI_ClinicallyRelevantEffect_VoR.pdf
- Size:
- 240.1 KB
- Format:
- Adobe Portable Document Format
